Fig. 6.
Fig. 6. The Ado receptor antagonists CGS15943 and CSC reverse the suppressive effect of CGS21680 on fMLP-stimulated PLD activity. / 1-O-[3H]alkyl-2-lysophosphatidylcholine-labeled neutrophils were prewarmed at 37°C for 5 minutes. (A) The cell suspensions were pretreated with 10 μmol/L CB and 0.1 U/mL ADA in the presence or absence of 0.1μmol/L CGS21680 for an additional 5 minutes. Where indicated, 0.1 and 1 μmol/L CGS15943 was also added to neutrophil suspensions 5 minutes before stimulation with 0.1 μmol/L fMLP for 10 minutes in the presence of 1% ethanol. (B) The experimental conditions were similar to A. Where indicated, 10 μmol/L CSC was added to neutrophil suspensions 5 minutes before stimulation with 0.1 μmol/L fMLP for 10 minutes in the presence of 1% ethanol. The amount of radioactivity incorporated into [3H]PEt was assessed as described in “Materials and Methods” and is expressed as the percentage of the radioactivity in the total lipid extracts. The data are the means ± SEM of 3 separate experiments.

The Ado receptor antagonists CGS15943 and CSC reverse the suppressive effect of CGS21680 on fMLP-stimulated PLD activity.

1-O-[3H]alkyl-2-lysophosphatidylcholine-labeled neutrophils were prewarmed at 37°C for 5 minutes. (A) The cell suspensions were pretreated with 10 μmol/L CB and 0.1 U/mL ADA in the presence or absence of 0.1μmol/L CGS21680 for an additional 5 minutes. Where indicated, 0.1 and 1 μmol/L CGS15943 was also added to neutrophil suspensions 5 minutes before stimulation with 0.1 μmol/L fMLP for 10 minutes in the presence of 1% ethanol. (B) The experimental conditions were similar to A. Where indicated, 10 μmol/L CSC was added to neutrophil suspensions 5 minutes before stimulation with 0.1 μmol/L fMLP for 10 minutes in the presence of 1% ethanol. The amount of radioactivity incorporated into [3H]PEt was assessed as described in “Materials and Methods” and is expressed as the percentage of the radioactivity in the total lipid extracts. The data are the means ± SEM of 3 separate experiments.

Close Modal

or Create an Account

Close Modal
Close Modal